Skip to content
HowShorted

Nektar Therapeutics short interest in 2023

In 2023, Nektar Therapeutics's disclosed short interest ran from 4.91% of shares outstanding on 13 Jan 2023 to 2.80% on 29 Dec 2023, a change of -2.11 percentage points. The year's high was 5.83% on 15 Jun 2023 and its low 2.79% on 14 Jul 2023, averaging 4.20% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 8.87 days on 29 Sep 2023. Full history: Nektar Therapeutics.

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Nektar Therapeutics in 2023

2023 in figures

Start of year
4.91% (13 Jan 2023)
End of year
2.80% (29 Dec 2023)
Change
-2.11 pp
High
5.83% (15 Jun 2023)
Low
2.79% (14 Jul 2023)
Average
4.20%
Highest days to cover
8.87 (29 Sep 2023)
SEC filings marked
10

Every report in 2023

Nektar Therapeutics short interest in 2023
SettlementShort interestDays to coverFilings since previous
13 Jan 20234.91%7.07results (8-K)
31 Jan 20235.29%7.55
15 Feb 20235.28%7.01
28 Feb 20234.66%1.9210-K filed, results (8-K)
15 Mar 20233.77%2.57
31 Mar 20234.53%1.24
14 Apr 20234.37%1.00
28 Apr 20235.10%3.68results (8-K)
15 May 20235.34%4.43results (8-K), 10-Q filed
31 May 20235.23%3.13
15 Jun 20235.83%2.74
30 Jun 20232.87%1.00
14 Jul 20232.79%3.14
31 Jul 20233.06%3.18
15 Aug 20233.76%1.00results (8-K), 10-Q filed
31 Aug 20233.56%2.41
15 Sep 20233.82%3.29
29 Sep 20234.07%8.87
13 Oct 20234.31%5.83
31 Oct 20233.91%3.39
15 Nov 20234.20%4.50results (8-K), 10-Q filed
30 Nov 20233.79%5.48
15 Dec 20233.65%5.63
29 Dec 20232.80%4.37

See also: Nektar Therapeutics's full history · most shorted US stocks of 2023 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.